Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesFortrea Holdings Inc.

Fortrea Holdings Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
20.38 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1517720
Market Cap
1876.32M

Momentum Score

…

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.36
Low
21.58
High
52 Week Price Range
8.30
Low
21.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fortrea Holdings Inc. is a contract research and clinical development organization providing outsourced services to pharmaceutical and biotechnology companies. Long-term growth drivers include increasing R&D outsourcing, rising trial complexity, and demand for specialized capabilities such as biologics that could support growth. Investors may find the company attractive because it appears positioned to capture outsourcing trends through scale, multi-service offerings and diversified client relationships.

Most important risks include intense competition and pricing pressure, dependence on clients' R&D spending cycles and contract concentration, plus operational and regulatory execution risks investors should monitor.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
20.38
Dividend Yield
-
Revenue TTM
2676.50M
Revenue Per Share
28.75
Gross Profit TTM
516.60M
Debt / Equity
0.12
ROE
-15.30%
Net Debt
-106.60M
ROCE
-49.47%
Diluted EPS TTM
-0.94

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -983.00M -275.00M -30.50M 58.90M 136.40M
Net income -986.20M -328.50M -25.20M 58.40M 98.00M
Selling general administrative 456.40M 560.70M 336.60M 299.90M 303.10M
Gross profit 425.80M 534.20M 590.60M 621.70M 604.40M
Reconciled depreciation 78.00M 86.90M 96.40M 92.70M 166.30M
Ebit -891.60M -151.20M 39.20M 236.10M 135.50M
Ebitda -813.60M -64.30M 137.20M 328.80M 301.80M
Depreciation and amortization 78.00M 86.90M 98.00M 92.70M 166.30M
Operating income -30.60M -161.90M 32.00M 185.20M 114.30M
Other operating expenses 2754.00M 2858.30M 2810.50M 2870.60M 2922.50M
Interest expense 91.40M 123.80M 69.80M 132.40M -
Tax provision 3.20M -3.50M 4.50M 0.50M 38.40M
Net interest income -91.40M -123.80M -69.80M -132.40M -
Income tax expense 3.20M -3.50M 1.20M 0.50M 38.40M
Total revenue 2723.40M 2696.40M 2842.50M 3096.10M 3057.50M
Total operating expenses 456.40M 696.10M 558.60M 396.20M 469.40M
Cost of revenue 2297.60M 2162.20M 2251.90M 2474.40M 2453.10M
Total other income expense net -952.40M -113.10M -62.50M -34.20M 1.40M
Net income from continuing ops -986.20M -271.50M -3.40M 58.40M 98.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2715.70M 3579.20M 4357.20M 4287.90M 4368.70M
Intangible assets 622.00M 655.70M 771.20M 823.30M 935.50M
Other current assets 132.90M 135.70M 35.10M 83.50M 73.10M
Total liab 2152.20M 2216.80M 2618.40M 945.30M 1108.10M
Total stockholder equity 563.50M 1362.40M 1738.80M 3342.60M 3260.60M
Other current liab 395.80M 317.10M 356.10M 322.70M 435.20M
Common stock 0.10M 0.10M 0.10M - -
Capital stock 0.10M 0.10M 0.10M - -
Retained earnings -1383.20M -397.00M -49.10M - -
Good will 960.00M 1710.40M 2029.30M 1997.30M 2080.90M
Cash 174.60M 118.50M 108.60M 112.00M 94.60M
Total current liabilities 913.30M 949.50M 775.90M 699.00M 826.70M
Current deferred revenue 473.80M 353.30M 241.40M 271.50M 307.00M
Net debt -106.60M 1080.00M 1569.40M -48.60M -17.40M
Short term debt 14.00M 88.20M 45.60M 23.30M 24.00M
Short long term debt 4.80M 74.80M 26.10M - -
Short long term debt total 68.00M 1198.50M 1678.00M 63.40M 77.20M
Other stockholder equity 2116.60M 2042.20M 2006.20M 3618.60M 3409.00M
Total current assets 897.20M 948.20M 1253.10M 1246.90M 1117.50M
Net receivables 589.70M 694.00M 1074.10M 1051.40M 949.80M
Long term debt 1048.00M 1049.70M 1565.90M - -
Inventory - - 35.30M - -
Accounts payable 29.70M 138.20M 132.80M 81.50M 60.50M
Accumulated other comprehensive income -170.00M -282.90M -218.40M -276.00M -148.40M
Non currrent assets other 80.80M 103.40M 79.50M 54.30M 70.80M
Non current assets total 1818.50M 2631.00M 3104.10M 3041.00M 3251.20M
Capital lease obligations 63.20M 74.00M 86.00M 63.40M 77.20M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 251.60M -31.80M -54.00M -26.20M
Total cashflows from investing activities 14.40M 251.60M -31.80M - -
Net borrowings -75.70M -482.70M 1616.00M - -
Total cash from financing activities -76.30M -497.80M -140.80M -8.70M -128.50M
Net income -986.20M -271.50M -25.20M 192.90M 98.00M
Change in cash 56.10M 9.90M -1.80M 17.40M 14.30M
Begin period cash flow 118.50M 108.60M 110.40M 94.60M 80.30M
End period cash flow 174.60M 118.50M 108.60M 112.00M 94.60M
Total cash from operating activities 113.50M 262.80M 168.40M 87.50M 169.80M
Depreciation 78.00M 98.00M 98.00M 92.70M 166.30M
Other cashflows from investing activities 39.60M 0.50M 8.50M - -
Change to account receivables 70.90M 309.90M -53.40M - -
Other cashflows from financing activities -76.30M -15.10M -1756.80M -8.70M -128.50M
Capital expenditures 25.20M 25.50M 40.30M 54.40M 26.50M
Change in working capital 114.70M 364.50M 26.90M -245.80M -127.20M
Stock based compensation 74.40M 58.40M 42.70M 25.40M 27.50M
Other non cash items 864.60M 38.00M 67.60M 38.80M 35.40M
Free cash flow 88.30M 237.30M 128.10M 33.10M 143.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FTRE
Fortrea Holdings Inc.		 -
-%		 20.38 - 10.82 0.70 3.16 0.97 30.76
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Fortrea Holdings Inc.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

8 Moore Drive, Durham, NC, United States, 27709

877 495 0816

https://www.fortrea.com

14000

Name Title Year Born
Mr. Thomas H. Pike CEO, President & Chairman 1959
Ms. Jill McConnell Chief Financial Officer 1975
Mr. Mark A. Morais COO & President of Clinical Services 1977
Amanda M. Warren Chief Accounting Officer NA
Ms. Hima B. Inguva Head of Investor Relations & Corporate Development NA
Stillman Hanson General Counsel & Corporate Secretary NA
Dr. John J. Doyle President of Consulting NA
Mr. Anshul Thakral CEO & Director 1978
Mr. Drayton Virkler President & Chief Commercial Officer NA
Mr. Robert Parks Chief Accounting Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…